Segall Bryant & Hamill LLC grew its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 15.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 175,656 shares of the company's stock after purchasing an additional 23,967 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.08% of QIAGEN worth $7,053,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in QIAGEN by 221.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 184,966 shares of the company's stock worth $8,237,000 after acquiring an additional 127,453 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in QIAGEN in the 4th quarter worth $1,521,000. Raymond James Financial Inc. purchased a new position in QIAGEN in the 4th quarter worth $11,057,000. PNC Financial Services Group Inc. grew its position in QIAGEN by 7.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,498 shares of the company's stock worth $467,000 after purchasing an additional 742 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in QIAGEN by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after purchasing an additional 526 shares during the period. Hedge funds and other institutional investors own 70.00% of the company's stock.
QIAGEN Stock Performance
Shares of NYSE QGEN traded down $0.30 during midday trading on Monday, reaching $48.06. 1,533,300 shares of the company were exchanged, compared to its average volume of 1,226,097. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $49.30. The stock has a fifty day simple moving average of $45.95 and a 200 day simple moving average of $42.98. The stock has a market cap of $10.68 billion, a P/E ratio of 20.92, a PEG ratio of 2.46 and a beta of 0.68.
QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. QIAGEN had a return on equity of 14.61% and a net margin of 4.68%. The company had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same quarter in the previous year, the company earned $0.44 EPS. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts forecast that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.
QIAGEN Announces Dividend
The business also recently disclosed a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 0.52%. QIAGEN's dividend payout ratio is presently 62.50%.
Wall Street Analyst Weigh In
A number of research firms have recently commented on QGEN. Redburn Atlantic cut QIAGEN from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Bank of America raised their target price on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Wall Street Zen upgraded QIAGEN from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Robert W. Baird raised their target price on QIAGEN from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Finally, Barclays assumed coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $49.40.
Check Out Our Latest Research Report on QGEN
QIAGEN Company Profile
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
